BION Net Income Per Share from 2010 to 2026

BION Stock  CHF 47.05  0.70  1.51%   
BB Biotech Net Income Per Share yearly trend continues to be fairly stable with very little volatility. Net Income Per Share is likely to outpace its year average in 2026. During the period from 2010 to 2026, BB Biotech Net Income Per Share regression line of quarterly data had mean square error of  107.93 and geometric mean of  5.86. View All Fundamentals
 
Net Income Per Share  
First Reported
2010-12-31
Previous Quarter
1.59
Current Value
3.1
Quarterly Volatility
10.46030644
 
Credit Downgrade
 
Yuan Drop
 
Covid
 
Interest Hikes
Check BB Biotech financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among BB Biotech's main balance sheet or income statement drivers, such as Interest Expense of 6 M, Selling General Administrative of 25.7 M or Total Revenue of 169.9 M, as well as many indicators such as Price To Sales Ratio of 14.91, Dividend Yield of 0.0337 or PTB Ratio of 0.75. BION financial statements analysis is a perfect complement when working with BB Biotech Valuation or Volatility modules.
  
This module can also supplement various BB Biotech Technical models . Check out the analysis of BB Biotech Correlation against competitors.
The evolution of Net Income Per Share for BB Biotech AG provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how BB Biotech compares to historical norms and industry peers.

Latest BB Biotech's Net Income Per Share Growth Pattern

Below is the plot of the Net Income Per Share of BB Biotech AG over the last few years. It is BB Biotech's Net Income Per Share historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in BB Biotech's overall financial position and show how it may be relating to other accounts over time.
Net Income Per Share10 Years Trend
Slightly volatile
   Net Income Per Share   
       Timeline  

BION Net Income Per Share Regression Statistics

Arithmetic Mean3.73
Geometric Mean5.86
Coefficient Of Variation280.75
Mean Deviation8.39
Median1.59
Standard Deviation10.46
Sample Variance109.42
Range40.4721
R-Value(0.27)
Mean Square Error107.93
R-Squared0.08
Significance0.29
Slope(0.57)
Total Sum of Squares1,751

BION Net Income Per Share History

2026 3.1
2025 1.59
2023 -3.77
2022 -6.5
2021 -7.31
2020 12.48
2019 12.23

About BB Biotech Financial Statements

BB Biotech investors use historical fundamental indicators, such as BB Biotech's Net Income Per Share, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in BB Biotech. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Net Income Per Share 1.59  3.10 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for BION Stock Analysis

When running BB Biotech's price analysis, check to measure BB Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BB Biotech is operating at the current time. Most of BB Biotech's value examination focuses on studying past and present price action to predict the probability of BB Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BB Biotech's price. Additionally, you may evaluate how the addition of BB Biotech to your portfolios can decrease your overall portfolio volatility.